In an article published by Chen et al, the serum of 26 patients who recovered from COVID-19 were analyzed for the production of IgG anti-SARS-CoV-2 S1 protein antibodies. It was found that, despite the majority of patients presenting high IgG titers, only three individuals had antibodies that effectively neutralized the binding of the viral glycoprotein to the human ACE2 receptor. In addition, the authors successfully managed to clone two different neutralizing antibodies from these patients with the ability to inhibit virus-cell binding, opening up the potential for using them as a possible source of treatment for COVID-19 (203).